AbbVie Inc (ABBV)vsWORK Medical Technology Group LTD Ordinary Shares (WOK)
ABBV
AbbVie Inc
$211.32
+3.64%
HEALTHCARE · Cap: $360.63B
WOK
WORK Medical Technology Group LTD Ordinary Shares
$1.21
+3.42%
HEALTHCARE · Cap: $1.56M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 620896% more annual revenue ($61.16B vs $9.85M). ABBV leads profitability with a 6.9% profit margin vs -10.9%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
WOK
Avoid29
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-29.3%
Fair Value
$163.42
Current Price
$211.32
$47.90 premium
Intrinsic value data unavailable for WOK.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 34.1%
Conservative balance sheet, low leverage
Generating 4.9B in free cash flow
Reasonable price relative to book value
Areas to Watch
6.9% margin — thin
Premium valuation, high expectations priced in
Earnings declined 88.7%
Distress zone — elevated risk
Grey zone — moderate risk
Smaller company, higher risk/reward
ROE of -6.5% — below average capital efficiency
Revenue declined 14.4%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : WOK
The strongest argument for WOK centers on Price/Book.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 100.0x leaves little room for execution misses.
Bear Case : WOK
The primary concerns for WOK are Altman Z-Score, Market Cap, Return on Equity.
Key Dynamics to Monitor
ABBV profiles as a value stock while WOK is a turnaround play — different risk/reward profiles.
ABBV is growing revenue faster at 10.0% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABBV scores higher overall (63/100 vs 29/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
WORK Medical Technology Group LTD Ordinary Shares
HEALTHCARE · MEDICAL DEVICES · USA
WORK Medical Technology Group Ltd is a leading entity in the medical technology sector, dedicated to the research, development, and commercialization of cutting-edge healthcare solutions. The company specializes in advanced medical devices designed to enhance patient outcomes and address critical challenges in global healthcare. Its commitment to quality and innovation, combined with a diverse product portfolio, positions WORK for sustained growth, making it an attractive investment opportunity for institutional investors seeking to engage in transformative advancements within the healthcare landscape.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?